论文部分内容阅读
作者用连续注射 IL-2和 LAK 细胞的过继免疫疗法治疗10例肝细胞癌。其中3例未曾做其他治疗;4例有明显的门脉栓塞,曾接受经肝动脉注射阿霉素的治疗;2例做过外科手术;1例做过肝管动脉栓塞治疗。从肝细胞癌病人血中分离的单个核细胞与IL-2,经5%CO_2、37℃共同孵育4～5天,成为 LAK 细胞,通过动脉或静脉再回输给患者,细胞数量平均为2.1×10~9/次,每周一次。IL-2经动脉或肌肉注射,平均剂量为1000～2000U/天。
The authors treated 10 cases of hepatocellular carcinoma with adoptive immunotherapy with continuous injection of IL-2 and LAK cells. Three of them had not done other treatments; 4 had obvious portal vein embolism and had received hepatic artery injection of doxorubicin; 2 had surgery; 1 had hepatic artery embolization. The mononuclear cells isolated from the blood of patients with hepatocellular carcinoma and IL-2 were incubated with 5% CO 2 and 37°C for 4 to 5 days to become LAK cells, which were then returned to the patient through an artery or vein. The average number of cells was 2.1. × 10~9/times, once a week. IL-2 is injected intra-arterially or intramuscularly with an average dose of 1000 to 2000 U/day.